The executive VHPB secretariat benefits from being seated at the Center for the Evaluation of Vaccination (CEV) of the University of Antwerpen, where it has the infrastructure and administrative services of the University at its disposal.
VHPB is supported by unrestricted grants from the vaccine industry (GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, Sanofi Pasteur and in the past als by Merck), several universities in Europe and other institutions.
The VHPB was set up in 1992, under the auspices of the Society for Occupational Medicine, with the aim to eliminate transmission of hepatitis B in all workers at risk in the industrialised world. From 1993 onwards, the scope was progressively extended, first to hepatitis B as a community health risk (under the auspices of the European Public Health Association), and later to hepatitis A and C.
The Viral Hepatitis Prevention Board (VHPB) is an international board of experts in viral hepatitis, offering a platform for dissemination of scientific infromation related to viral hepatitis. Board members meet twice a year to discuss technical and country specific issues.
WHO launched their new global policy report on the prevention and control of viral hepatitis.
WHO global policy report on the prevention and control of viral hepatitis in WHO Member States, is a report based on findings of a survey performed by WHO in collaboration with the World hepatitis alliance, mid-2012 and responded by 126 countries. The survey asked Member States to provide information relating to the four axes of the WHO strategy. In particular, Member States were asked whether key prevention and control activities are being conducted.